Telix Pharmaceuticals Limited (TLX) Friday said Health Canada has approved label expansion for its prostate cancer imaging product Illuccix to include patient selection for PSMA-targeted radionuclide therapy.
Illuccix is a kit for the preparation of gallium-68 gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer.
With the label extension approval, Illuccix can now be used to select patients with progressive metastatic castration-resistant prostate cancer (mCRPC) for treatment with the only approved PSMA-targeted radionuclide therapy, Pluvicto. To qualify for PSMA-targeted therapy, patients must be imaged with an approved gallium-based PSMA-PET agent such as Illuccix.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.